Financials aap Implantate AG Xetra

Equities

End-of-day quote Xetra Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
0.73 ^EUR	-2.67%		-9.32%	-12.05%

2021	Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021	CI
2021	Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020	CI

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	32.4	11.93	10.1	14.93	8.047	9.071	9.071	-
Enterprise Value (EV) ¹	28.49	11.28	11.69	16.99	11.04	13.97	16.07	16.67
P/E ratio	-4.19 x	-0.61 x	-1.13 x	-5.88 x	-3.46 x	-2.09 x	-4.6 x	-13.1 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	3.01 x	1.02 x	1.08 x	1.23 x	0.7 x	0.8 x	0.7 x	0.6 x
EV / Revenue	2.64 x	0.96 x	1.25 x	1.4 x	0.96 x	1.24 x	1.24 x	1.11 x
EV / EBITDA	-4.45 x	-2.19 x	-3.39 x	-14.2 x	-4.8 x	-5.17 x	-40.2 x	15.2 x
EV / FCF	-3.2 x	-2.06 x	-2.86 x	-6.07 x	-4.93 x	-5.17 x	-7.31 x	-33.3 x
FCF Yield	-31.2%	-48.4%	-35%	-16.5%	-20.3%	-19.3%	-13.7%	-3%
Price to Book	0.93 x	0.63 x	0.98 x	1.17 x	0.69 x	0.77 x	0.84 x	0.84 x
Nbr of stocks (in thousands)	2,867	3,207	3,207	4,978	5,961	9,860	9,860	-
Reference price ²	11.30	3.720	3.150	3.000	1.350	0.9200	0.9200	0.9200
Announcement Date	4/30/19	6/30/20	4/30/21	3/31/22	4/29/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	10.78	11.74	9.326	12.17	11.52	11.3	13	15
EBITDA ¹	-6.406	-5.142	-3.443	-1.2	-2.3	-2.7	-0.4	1.1
EBIT ¹	-8.132	-19.77	-7.886	-2.61	-3.388	-3.7	-1.5	-0.2
Operating Margin	-75.43%	-168.4%	-84.56%	-21.45%	-29.42%	-32.74%	-11.54%	-1.33%
Earnings before Tax (EBT) ¹	-7.648	-20.04	-8.816	-2.684	-3.613	-4.1	-1.9	-0.6
Net income ¹	-7.836	-19.52	-8.793	-2.522	-2.564	-3.9	-1.8	-0.6
Net margin	-72.68%	-166.28%	-94.28%	-20.73%	-22.26%	-34.51%	-13.85%	-4%
EPS ²	-2.700	-6.100	-2.790	-0.5100	-0.3900	-0.4400	-0.2000	-0.0700
Free Cash Flow ¹	-8.892	-5.465	-4.089	-2.799	-2.237	-2.7	-2.2	-0.5
FCF margin	-82.48%	-46.55%	-43.85%	-23.01%	-19.43%	-23.89%	-16.92%	-3.33%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Announcement Date	4/30/19	6/30/20	4/30/21	3/31/22	4/29/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	1.59	2.06	2.99	4.9	7	7.6
Net Cash position ¹	3.91	0.65	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-0.4604 x	-1.713 x	-1.3 x	-1.815 x	-17.5 x	6.909 x
Free Cash Flow ¹	-8.89	-5.47	-4.09	-2.8	-2.24	-2.7	-2.2	-0.5
ROE (net income / shareholders' equity)	-20.2%	-72.6%	-60.3%	-21.9%	-20%	-32.7%	-17.5%	-5.9%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	12.20	5.880	3.210	2.570	1.950	1.200	1.100	1.100
Cash Flow per Share	-	-	-	-	-	-	-	-
Capex ¹	2.97	1.69	0.33	0.33	0.34	0.3	0.3	0.4
Capex / Sales	27.58%	14.39%	3.58%	2.7%	2.99%	2.65%	2.31%	2.67%
Announcement Date	4/30/19	6/30/20	4/30/21	3/31/22	4/29/23	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.92 EUR

Average target price

0.8 EUR

Spread / Average Target

-13.04%

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
TERUMO CORPORATION	+12.96%	24.62B